Trial Profile

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Apr 2022 Results assessing effects of initiation of anti-seizure medications in Atrial Fibrillation-related stroke presented at the 74th Annual Meeting of the American Academy of Neurology 2022
04 Apr 2022 Results assessing quality of life and anticoagulation in atrial fibrillation Patients presented at the 71st Annual Scientific Session of the American College of Cardiology
11 Feb 2022 Results of sub study, finding whether there is also an association between AF burden and recurrent cerebrovascular events in anticoagulated AF patients after their initial acute ischemic stroke (AIS) or transient ischemic attacks (TIA), presented at the International Stroke Conference 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com